Peptide Aptamers Against Tenascin C

Abstract

The present invention relates to an anti-tenascin C peptide aptamer having a specific amino acid sequence and a diagnosis kit comprising it. The anti-tenascin C peptide aptamer of the instant invention shows a predominant clearance rate due to its small molecular weight as well as specific binding affinity to tenascin C, having excellent advantages in in vivo or ex vivo tumor imaging.

1 . An anti-tenascin C peptide aptamer represented by the following Formula 1:
   X aa1 -HiS-LyS-X aa2 —X aa3 —X aa4 —X aa5 —X aa6 —X aa7 —X aa8 —X aa9 —X aa10   Formula 1   wherein X aa1  represents Phe, Trp, Leu or Thr, and X aa2  represents Pro, His, Thr or Ile, and X aa3  represents any amino acid selected from 20 amino acids, and X aa4  represents Phe, Ser, Pro, Trp, Lys, Arg or Gln, and X aa5  represents Pro, Arg, Ser, Thr, Lys or Ile, and X aa6  represents any amino acid selected from 20 amino acids, and X aa7  represents any amino acid selected from 20 amino acids, and X aa8  represents any amino acid selected from 20 amino acids, and X aa9  represents Arg, Pro, Phe, Leu, Val, Thr, Asn or Ser, and X aa10  represents any amino acid selected from 20 amino acids.   
     
     
         2 . The peptide aptamer according to  claim 1 , wherein X aa1  represents Phe. 
     
     
         3 . The peptide aptamer according to  claim 1 , wherein X aa2  represents Pro or His. 
     
     
         4 . The peptide aptamer according to  claim 1 , wherein X aa3  represents Phe, Lys, Ser, Gln, Pro or Arg. 
     
     
         5 . The peptide aptamer according to  claim 1 , wherein X aa4  represents Ser. 
     
     
         6 . The peptide aptamer according to  claim 1 , wherein X aa5  represents Pro. 
     
     
         7 . The peptide aptamer according to  claim 1 , wherein X aa6  represents Lys, Ala, Ser, Pro, Tyr, Ile, H is or Thr. 
     
     
         8 . The peptide aptamer according to  claim 1 , wherein X aa7  represents Gly, Leu, Pro, Arg, Thr, Met or His. 
     
     
         9 . The peptide aptamer according to  claim 1 , wherein X aa8  represents Ser, Ile, Gly, Gln, Leu, Pro or Arg. 
     
     
         10 . The peptide aptamer according to  claim 1 , wherein X aa9  represents Pro. 
     
     
         11 . The peptide aptamer according to  claim 1 , wherein X aa10  represents Arg, Val, Ile, Ser, Phe, Lys, Gln, Leu, Pro or Ala. 
     
     
         12 . The peptide aptamer according to  claim 1 , wherein the peptide aptamer comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:1-11. 
     
     
         13 . The peptide aptamer according to  claim 1 , wherein the peptide aptamer further comprises Gly residue(s) in its N-terminal. 
     
     
         14 . The peptide aptamer according to  claim 13 , wherein the peptide aptamer further comprises 2-4 Gly residues. 
     
     
         15 . A diagnosis kit for detecting a tumor, comprising the peptide aptamer according to  claim 1 . 
     
     
         16 . The kit according to  claim 15 , wherein the tumor is stomach cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchogenic cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, uterine cervical cancer, brain cancer, prostaic cancer, bone cancer, skin cancer, thyroid cancer, parathyroid cancer or ureter cancer. 
     
     
         17 . The kit according to  claim 16 , wherein the tumor is glioblastoma, colon adenocarcinoma or lung carcinoma. 
     
     
         18 . The peptide aptamer according to  claim 4 , wherein the peptide aptamer comprises the amino acid sequence of SEQ ID NO:1 or NO: 2.